aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference

SAN DIEGO, March 1, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's presentation at the Cowen and Company 37^th Annual Health Care Conference to be held from March 6 – 8, 2017 at the Boston Marriott Copley Place.

The aTyr management team will present an overview of the Company during a presentation at 8:00 a.m. ET on Tuesday, March 7, 2017. The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com.  An audio replay will be available for at least 30 days following the initial presentation webcast. 

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 80 issued or allowed patents and over 230 pending patent applications that are owned or exclusively licensed by aTyr, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.

Contact:
Mark Johnson
Sr. Director, Investor Relations
mjohnson@atyrpharma.com
858-223-1163

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atyr-pharma-to-present-at-cowen-and-company-37th-annual-health-care-conference-300415639.html

SOURCE aTyr Pharma, Inc.